Patrick C. May, Ph.D., is President and owner of ADvantage Neuroscience Consulting LLC, an independent consulting firm in Fort Wayne, IN, focusing on drug discovery in Alzheimer’s disease and related neurodegenerative diseases. Dr. May is currently serving as a drug discovery consultant for the Rainwater Charitable Foundation Tau Consortium and sits on their Scientific Advisory Board. He has also been a member since 2009 of the NIA UO1 AD Drug Discovery Special Emphasis Panel. Dr. May retired from Eli Lilly and Co. in 2014 as a Senior Research Fellow in the Neuroscience Discovery Research area. During his productive 25-year career at Lilly, he helped to build and establish one of the industry’s leading Alzheimer’s disease drug discovery programs, delivering numerous candidates for clinical testing in AD. He has authored or co-authored over 100 research articles and book chapters. Prior to joining Lilly, Dr. May received post-doctoral training in gerontology, Alzheimer’s disease, and molecular neuroscience with Dr. Caleb Finch at the Andrus Gerontology Center of the University of Southern California (1982-1989). Dr. May received his Ph.D. in 1982 from the Department of Biochemistry and Molecular Biology at the University of Oklahoma Health Sciences Center where his research focused on mechanisms of cell death in Huntington’s disease. In summary, Dr. May’s entire academic and industry career has been spent with an unwavering focus on discovering a better understanding of neurodegenerative processes and identifying tractable approaches for their treatment.
